// STARTUP COMPARISON
Outcome Health vs Limeade Israel
Outcome Health failed in 2022 due to Fraud. Limeade Israel failed in 2021 due to Acquisition Gone Wrong. Different causes, different sectors, different eras — but the same simulation outcome.
| METRIC | 🔥 Outcome Health | 🔥 Limeade Israel |
|---|---|---|
| Sector | Healthtech | Healthtech |
| Country | USA | Israel |
| Founded | 2006 | 2014 |
| Died | 2022 | 2021 |
| Raised | $487M | $30M |
| Peak | $5.5B valuation | $30M raised |
| Primary Cause | Fraud | Acquisition Gone Wrong |
// WHY EACH FAILED
🔥 Outcome Health
Fraud
Outcome Health, a Chicago-based healthcare media company, installed screens in doctors' waiting rooms and sold advertising to pharmaceutical companies. After raising $487M at $5.5B valuation, it emerged the company had systematically overbilled pharma clients for ads on non-existent or under-performing screens. Co-founders Rishi Shah and Shradha Agarwal were convicted of fraud in 2023.
// LESSON
Ad businesses that cannot provide independent third-party verification of delivery create a structural fraud incentive. If your clients cannot verify what they are paying for, the business model creates the conditions for fraud regardless of founder intent.
Ad businesses that cannot provide independent third-party verification of delivery create a structural fraud incentive. If your clients cannot verify what they are paying for, the business model creates the conditions for fraud regardless of founder intent.
🔥 Limeade Israel
Acquisition Gone Wrong
Limeade built an employee wellbeing and engagement platform with significant Israeli R&D operations. After raising $30M, Roper Technologies acquired the company in 2021. Post-acquisition the Israeli engineering center was deprioritized as Roper focused on integrating Limeade's US commercial operations. Key Israeli engineers departed and the product development velocity declined significantly.
// LESSON
Israeli R&D centers acquired by US companies need explicit contractual protection of headcount and roadmap independence. Without it, the US commercial integration absorbs all management attention and the R&D center becomes a cost center that gets rationalized.
Israeli R&D centers acquired by US companies need explicit contractual protection of headcount and roadmap independence. Without it, the US commercial integration absorbs all management attention and the R&D center becomes a cost center that gets rationalized.
// EXPLORE FURTHER